Weekly Investment Analysts’ Ratings Changes for Lexeo Therapeutics (LXEO)

Lexeo Therapeutics (NASDAQ: LXEO) recently received a number of ratings updates from brokerages and research firms:

• 4/8/2025 – Lexeo Therapeutics had its price target lowered by analysts at Chardan Capital from $25.00 to $22.00. They now have a “buy” rating on the stock.
• 4/8/2025 – Lexeo Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
• 3/26/2025 – Lexeo Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
• 3/25/2025 – Lexeo Therapeutics had its price target lowered by analysts at Royal Bank of Canada from $24.00 to $20.00. They now have an “outperform” rating on the stock.
• 3/25/2025 – Lexeo Therapeutics had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $25.00 price target on the stock.
• 3/24/2025 – Lexeo Therapeutics had its price target lowered by analysts at Leerink Partners from $19.00 to $18.00. They now have an “outperform” rating on the stock.

Lexeo Therapeutics Trading Down 8.1 %

LXEO opened at $2.17 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95. Lexeo Therapeutics, Inc. has a one year low of $1.45 and a one year high of $19.50. The company has a market cap of $72.04 million, a P/E ratio of -0.69 and a beta of 1.52. The business’s 50-day simple moving average is $3.40 and its 200-day simple moving average is $6.02.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.09. As a group, equities research analysts expect that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Lexeo Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Allostery Investments LP purchased a new position in shares of Lexeo Therapeutics during the fourth quarter worth about $33,000. BNP Paribas Financial Markets boosted its position in shares of Lexeo Therapeutics by 184.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock valued at $50,000 after purchasing an additional 3,591 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in Lexeo Therapeutics during the 4th quarter worth approximately $46,000. JPMorgan Chase & Co. increased its position in Lexeo Therapeutics by 135.6% during the third quarter. JPMorgan Chase & Co. now owns 10,278 shares of the company’s stock worth $93,000 after buying an additional 5,915 shares during the period. Finally, Price T Rowe Associates Inc. MD purchased a new stake in Lexeo Therapeutics in the fourth quarter valued at approximately $69,000. 60.67% of the stock is currently owned by institutional investors and hedge funds.

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.